Agios Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Agios Pharmaceuticals

31/07/2025 14:32

Agios Pharmaceuticals Inc AGIO.OQ reported a quarterly adjusted loss of $1.93​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-1.69.  The mean expectation of eight analysts for the quarter was for a loss of $1.81 per share. Wall Street expected results to range from $-1.93 to $-1.67 per share.

Revenue rose 44.6% to $12.46 million from a year ago; analysts expected $9.48 million.

Agios Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.93​.

The company reported a quarterly loss of $112.02 million.

Agios Pharmaceuticals Inc shares had risen by 12.9% this quarter and gained 14.2% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 1.9% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Agios Pharmaceuticals Inc is $53.50, about 29.8% above its last closing price of $37.54

This summary was machine generated from LSEG data July 31 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-1.81
-1.93
Missed
Mar. 31 2025
-1.78
-1.55
Beat
Dec. 31 2024
-1.69
-1.44
Beat
Sep. 30 2024
1.11
-2.42
Missed